Kaneka Intends to Appeal Invalidity Decision in Lawsuit Against CoCrystal
Kaneka Intends to Appeal Invalidity Decision in Lawsuit Against CoCrystal
PR Newswire
TOKYO, Sept. 8, 2026
TOKYO, Sept. 8, 2026 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a complaint against Cocrystal Technology (Jiaxing) Co., Ltd. and Cocrystal Health Industry (Zhejiang) Co., Ltd. (collectively "CoCrystal") in the U.S. District Court for the Eastern District of New York (1:23-cv-7483-SJB-SDE) alleging that their supplements containing reduced coenzyme Q10, also known as "ubiquinol", infringe claims 5 and 15 of Kaneka's U.S. Patent No. 7,829,080 (the "'080 Patent" or "Patent").
On September 2, 2026, the New York District Court dismissed this litigation, holding that the Patent is invalid for lack of enablement. This decision was issued despite the fact that Kaneka submitted tests showing significant utility during the Patent's application and that a District Court in Delaware had previously held the Patent valid.
Kaneka strongly disagrees with the New York District Court's legal decision and interpretation of the evidence supporting the Patent's validity and significant utility. Kaneka will immediately appeal the decision to the Federal Circuit Court of Appeals.
The protection of Kaneka's intellectual property stands as a paramount cornerstone of its business. Kaneka's commitment to safeguarding these rights is unwavering, and it will not hesitate to take decisive legal action against anyone who fails to respect Kaneka's intellectual property, including its '080 Patent and other patents pertaining to reduced coenzyme Q10. In the lawsuit against CoCrystal, Kaneka is fully prepared to, and will, vigorously enforce its patent rights to the fullest extent.
Case Number: 1:23-cv-07483-SJB-SDE
SOURCE Kaneka Nutrients
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States